Introducing SMi's 6th annual conference on Pharmaceutical Freeze Drying Technology this June 2018

SMi Group13 - 14 June 2018, London, UK.
Although an old process, pharmaceutical freeze drying is ever evolving with new trends and approaches being used for pharmaceutical formulation. In it's 6th year, the conference will cover the most recent advances in Freeze drying technology and discuss the latest ideas in the industry. It is the perfect platform to strengthen knowledge in key principles such as PAT and QbD, whilst staying at the forefront of technological breakthroughs to adapt to growing manufacturing demands.

Gathering a room of Senior Scientists and Heads of Pharmaceutical Engineering, the 6th annual show provides an ideal forum to discuss the latest advancements in pharmaceutical lyophilisation, welcoming regulatory guidance from the NIBSC-MHRA and expertise from the likes of Sanofi, Boehringer Ingelheim, Janssen, GSK and more.

Network & Benefit From Industry Experts:

  • [CHAIR] SuneKlint Anderson, Principal Scientist, Janssen
  • Paul Matejtschuk, Principal Scientist, NIBSC - MHRA
  • Mostafa Nakach, Head of Pharmaceutical Engineering, Sanofi
  • ErwanBourles, Expert Scientist, Head Filling Drying Device, GlaxoSmithKline
  • MiguelaVieru, Senior Scientist, Janssen
  • Eric Munson, Patrick Deluca Endowed Professor of Pharmaceutical Technology, University of Kentucky
  • Patrick Garidel, Bioprocess and Pharmaceutical Development Biologicals, Boehringer Ingelheim
  • Daryl Williams, Reader in Particle Science, Imperial College London

Featured Highlights this June:

  • Discuss the use of old and new methods in terms of the optimisation of freeze drying cycles
  • Learn about case studies which delve into the processes through which cycles can be refined to the utmost efficiency
  • Hear about a new PAT for freeze drying cycle development through vial impedance spectroscopy
  • Discover ways in which water activity measurement and mathematical modelling can be used to evaluate the stability of freeze dried vaccines
  • Evaluate quality-by-design strategies, applied to spray drying, versus lyophilisation

Don't forget to check out the two-post conference interactive workshops taking place on 12th June.

For those looking to attend there are early-bird rates currently available of up to £400.

Further information is available at: www.pharmafreezedrying.com/wpn

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Chemists characterize the fatal fungus among us

Life-threatening fungal infections affect more than two million people worldwide. Effective antifungal medications are very limited. Until now, one of the major challenge...

FDA approves first cancer drug through new oncolog…

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopa...

Discovery of kidney cancer driver could lead to ne…

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic...

The immune system: T cells are built for speed

Without T cells, we could not survive. They are a key component of our immune system and have highly sensitive receptors on their surface that can detect pathogens. The e...

FDA approves first targeted treatment for patients…

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (...

Women and older people under-represented in drug t…

Trying to determine how best to treat a patient, doctors often look to randomized clinical trials to guide their choice of what drug to prescribe. One of the most common ...

Novartis renews drug donation of Egaten® (triclabe…

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) ...

Pfizer initiates pivotal Phase 3 program for inves…

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evalu...

Sanofi and REVOLUTION Medicines launch global part…

Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cell...

Novartis marks a new era for migraine patients wit…

Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days p...

FDA grants Breakthrough Therapy Designation for Ro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) i...

New findings suggest allergic responses may protec…

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings. The research, led by Imperial Col...